Savara (NASDAQ:SVRA) Trading Down 2.8%

Savara Inc (NASDAQ:SVRA)’s share price traded down 2.8% on Friday . The company traded as low as $4.91 and last traded at $4.93. 675,989 shares were traded during trading, a decline of 46% from the average session volume of 1,243,419 shares. The stock had previously closed at $5.07.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. HC Wainwright increased their price objective on shares of Savara from $6.00 to $10.00 and gave the company a “buy” rating in a research report on Thursday, June 27th. Guggenheim increased their price objective on shares of Savara from $8.00 to $10.00 and gave the company a “buy” rating in a research report on Thursday, June 27th. Oppenheimer increased their price objective on shares of Savara from $11.00 to $15.00 and gave the company an “outperform” rating in a research report on Wednesday, June 26th. JMP Securities restated a “market outperform” rating and set a $8.00 price objective on shares of Savara in a research report on Monday, May 6th. Finally, Evercore ISI lowered their price objective on shares of Savara from $10.00 to $7.00 and set an “outperform” rating on the stock in a research report on Thursday, May 16th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $11.00.

Savara Stock Performance

The company has a debt-to-equity ratio of 0.22, a current ratio of 14.90 and a quick ratio of 14.90. The company’s 50-day simple moving average is $4.30 and its two-hundred day simple moving average is $4.63.

Savara (NASDAQ:SVRA) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01). On average, equities analysts anticipate that Savara Inc will post -0.41 EPS for the current year.

Institutional Trading of Savara

A number of hedge funds and other institutional investors have recently modified their holdings of the company. ProShare Advisors LLC increased its stake in shares of Savara by 9.0% in the first quarter. ProShare Advisors LLC now owns 25,715 shares of the company’s stock worth $128,000 after purchasing an additional 2,114 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Savara by 15.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 33,692 shares of the company’s stock worth $168,000 after purchasing an additional 4,625 shares in the last quarter. CANADA LIFE ASSURANCE Co purchased a new stake in shares of Savara in the first quarter worth $35,000. AJOVista LLC purchased a new stake in shares of Savara in the fourth quarter worth $40,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in shares of Savara by 66.3% in the first quarter. China Universal Asset Management Co. Ltd. now owns 26,035 shares of the company’s stock worth $130,000 after purchasing an additional 10,381 shares in the last quarter. 87.93% of the stock is owned by hedge funds and other institutional investors.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.